{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T12:47:45Z","timestamp":1761310065095},"reference-count":87,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1006\/pupt.2002.0371","type":"journal-article","created":{"date-parts":[[2002,10,28]],"date-time":"2002-10-28T15:16:56Z","timestamp":1035818216000},"page":"409-416","source":"Crossref","is-referenced-by-count":16,"title":["What's in the Pipeline? Prospects for Monoclonal Antibodies (mAbs) as Therapies for Lung Diseases"],"prefix":"10.1006","volume":"15","author":[{"given":"Li","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuk M","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore J","family":"Torphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don E","family":"Griswold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/pupt.2002.0371_RF1","doi-asserted-by":"crossref","first-page":"1OS","DOI":"10.1378\/chest.117.2_suppl.10S","article-title":"Mechanisms in COPD: differences from asthma","volume":"117","author":"Barnes","year":"2000","journal-title":"Chest"},{"key":"10.1006\/pupt.2002.0371_RF2","first-page":"459","article-title":"Difficult, therapy-resistant asthma: definition and clinical features","volume":"55","author":"Chung","year":"2000","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1006\/pupt.2002.0371_RF3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1067\/mai.2000.111307","article-title":"Pathophysiology of severe asthma","volume":"106","author":"Busse","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1006\/pupt.2002.0371_RF4","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.98.12061322","article-title":"Costs of asthma according to the degree of severity","volume":"12","author":"Serra-Batlles","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1006\/pupt.2002.0371_RF5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1471-4892(01)00047-9","article-title":"Monoclonal antibodies as a strategy for pulmonary diseases","volume":"1","author":"Torphy","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1006\/pupt.2002.0371_RF6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(00)01034-5","article-title":"Therapeutic monoclonal antibodies","volume":"355","author":"Breedveld","year":"2000","journal-title":"Lancet"},{"key":"10.1006\/pupt.2002.0371_RF7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0167-5699(00)01667-4","article-title":"Natural and designer binding sites made by phage display technology","volume":"21","author":"Hoogenboom","year":"2000","journal-title":"Immunol Today"},{"key":"10.1006\/pupt.2002.0371_RF8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0022-1759(99)00137-4","article-title":"Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies","volume":"231","author":"Green","year":"1999","journal-title":"J Immunol Meth"},{"key":"10.1006\/pupt.2002.0371_RF9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM200007273430407","article-title":"Chronic obstructive pulmonary disease","volume":"343","author":"Barnes","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1006\/pupt.2002.0371_RF10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1471-4892(01)00045-5","article-title":"The role of epidermal growth factor in mucus production","volume":"1","author":"Nadel","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1006\/pupt.2002.0371_RF11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5507\/bp.2000.002","article-title":"Interleukin-1 family: from genes to human disease","volume":"143","author":"Laurincova","year":"2000","journal-title":"Acta Univ Palacki Olomuc Fac Med"},{"key":"10.1006\/pupt.2002.0371_RF12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.immunol.19.1.423","article-title":"Interleukin-18 regulates both Th1 and Th2 responses","volume":"19","author":"Nakanishi","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1006\/pupt.2002.0371_RF13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","article-title":"TNF alpha and the TNF receptor superfamily: structure-function relationship(s)","volume":"50","author":"Idriss","year":"2000","journal-title":"Microsci Res Tech"},{"key":"10.1006\/pupt.2002.0371_RF14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1378\/chest.118.4.971","article-title":"A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD","volume":"118","author":"Keatings","year":"2000","journal-title":"Chest"},{"key":"10.1006\/pupt.2002.0371_RF15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1164\/ajrccm.153.2.8564092","article-title":"Differences in Interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma","volume":"153","author":"Keatings","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1164\/ajrccm.163.2.2003122","article-title":"Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease","volume":"163","author":"Aaron","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/rr67","article-title":"Tumor necrosis factor-alpha and muscle wasting: a cellular perspective","volume":"2","author":"Reid","year":"2001","journal-title":"Respir Res"},{"key":"10.1006\/pupt.2002.0371_RF18","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1164\/ajrccm.150.5.7952575","article-title":"Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease","volume":"150","author":"Di Francia","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1164\/ajrccm.153.2.8564110","article-title":"Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients","volume":"153","author":"de Godoy","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF20","doi-asserted-by":"crossref","first-page":"L39","DOI":"10.1152\/ajplung.2001.280.1.L39","article-title":"Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension","volume":"280","author":"Fujita","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1006\/pupt.2002.0371_RF21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev.med.51.1.207","article-title":"Anti-cytokine therapy for rheumatoid arthritis","volume":"51","author":"Maini","year":"2000","journal-title":"Annu Rev Med"},{"key":"10.1006\/pupt.2002.0371_RF22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1517\/14656566.2.7.1137","article-title":"Etanercept in rheumatoid arthritis","volume":"2","author":"Alldred","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"10.1006\/pupt.2002.0371_RF23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1097-0029(20000801)50:3<229::AID-JEMT6>3.0.CO;2-H","article-title":"Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes","volume":"50","author":"Raza","year":"2000","journal-title":"Microsc Res Tech"},{"key":"10.1006\/pupt.2002.0371_RF24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00001610-199911000-00004","article-title":"Anti-TNF alpha: new therapy for Crohn's disease","volume":"22","author":"Mikula","year":"1999","journal-title":"Gastroenterol Nurs"},{"key":"10.1006\/pupt.2002.0371_RF25","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1006\/pupt.2002.0371_RF26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1165\/ajrcmb.22.3.3690","article-title":"Airway hyperresponsiveness and airway obstruction in transgenic mice. Morphologic correlates in mice overexpressing Interleukin (IL)-11 and IL-6 in the lung","volume":"22","author":"Kuhn","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1006\/pupt.2002.0371_RF27","first-page":"311","article-title":"Neutrophil receptors for Interleukin-8 and related CXC chemokines","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1006\/pupt.2002.0371_RF28","first-page":"P516","article-title":"Clinical trial results: a fully human anti-IL-8 antibody in patients with moderate to severe psoriasis","volume":"44","author":"Lohner","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1006\/pupt.2002.0371_RF29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/0470868678.ch10","article-title":"Lymphocytes, chronic bronchitis and chronic obstructive pulmonary disease","volume":"234","author":"Jeffery","year":"2001","journal-title":"Novartis Found Symp"},{"key":"10.1006\/pupt.2002.0371_RF30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4049\/jimmunol.158.1.376","article-title":"Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation","volume":"158","author":"Gunn","year":"1997","journal-title":"J Immunol"},{"key":"10.1006\/pupt.2002.0371_RF31","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1126\/science.277.5334.2002","article-title":"Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice","volume":"277","author":"Hautamaki","year":"1997","journal-title":"Science"},{"key":"10.1006\/pupt.2002.0371_RF32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/(SICI)1096-9896(200004)190:5<619::AID-PATH555>3.0.CO;2-6","article-title":"Monocyte chemoattractant protein 1, Interleukin 8, and chronic airways inflammation in COPD","volume":"190","author":"de Boer","year":"2000","journal-title":"J Pathol"},{"key":"10.1006\/pupt.2002.0371_RF33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1358\/mf.1999.21.8.794836","article-title":"Effect of anti-ICAM-1 on bronchial response: bronchoalveolar lavage fluid (BALF) and ultrastructural changes of bronchial epithelium in guinea pigs with dual phase bronchial response","volume":"21","author":"Tohda","year":"1999","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1006\/pupt.2002.0371_RF34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1367-5931(98)80120-8","article-title":"Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents","volume":"2","author":"Lin","year":"1998","journal-title":"Curr Opin Chem Biol"},{"key":"10.1006\/pupt.2002.0371_RF35","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1164\/ajrccm.158.6.9803014","article-title":"Sputum metalloproteinase-9\/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis","volume":"158","author":"Vignola","year":"1998","journal-title":"Am J Respir crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF36","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1172\/JCI10458","article-title":"Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema","volume":"106","author":"Zheng","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1006\/pupt.2002.0371_RF37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1084\/jem.194.6.809","article-title":"Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)","volume":"194","author":"Lee","year":"2001","journal-title":"J Exp Med"},{"key":"10.1006\/pupt.2002.0371_RF38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000024444","article-title":"Anti-IgE therapy in asthma: rationale and therapeutic potential","volume":"123","author":"Barnes","year":"2000","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1006\/pupt.2002.0371_RF39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000024049","article-title":"T cells and chronic asthma","volume":"118","author":"Kon","year":"1999","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1006\/pupt.2002.0371_RF40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s000110050496","article-title":"Anti-T cell strategies in asthma","volume":"48","author":"Kon","year":"1999","journal-title":"Inflamm Res"},{"key":"10.1006\/pupt.2002.0371_RF41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1165\/ajrcmb.10.6.8003337","article-title":"Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia","volume":"10","author":"Gavett","year":"1994","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1006\/pupt.2002.0371_RF42","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(97)12261-9","article-title":"Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma","volume":"352","author":"Kon","year":"1998","journal-title":"Lancet"},{"key":"10.1006\/pupt.2002.0371_RF43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/13543784.9.1.43","article-title":"CCR3 blockade as a new therapy for asthma","volume":"9","author":"Bertrand","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1006\/pupt.2002.0371_RF44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1006\/pupt.2001.0281","article-title":"Chemokine receptors in airway disease: which receptors to target?","volume":"14","author":"Owen","year":"2001","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1006\/pupt.2002.0371_RF45","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1067\/mai.2001.119156","article-title":"Reversal of human allergen-specific CRTH2 TH2 cells by IL-12 or the PS-DSP30 oligodeoxynucleotide","volume":"108","author":"Annunziato","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1006\/pupt.2002.0371_RF46","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1172\/JCI12655","article-title":"The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics","volume":"107","author":"Panina-Bordignon","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1006\/pupt.2002.0371_RF47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1365-2222.2000.00097.x","article-title":"The role of co-stimulation in airway inflammation","volume":"30","author":"Djukanovic","year":"2000","journal-title":"Clin Exp Allergy"},{"key":"10.1006\/pupt.2002.0371_RF48","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1165\/ajrcmb.21.4.3714","article-title":"CD28 interactions with either CD80 or CD86 are sufficient to induce allergic airway inflammation in mice","volume":"21","author":"Mathur","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1006\/pupt.2002.0371_RF49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1165\/ajrcmb.18.4.3055","article-title":"CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1\/Th2 subsets in a murine model of asthma","volume":"18","author":"Padrid","year":"1998","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1006\/pupt.2002.0371_RF50","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.4049\/jimmunol.163.11.6283","article-title":"Essential role for both CD80 and CD86 costimulation, but not CD40 interactions, in allergen-induced Th2 cytokine production from asthmatic bronchial tissue: role for alphabeta, but not gammadelta, T cells","volume":"163","author":"Jaffar","year":"1999","journal-title":"J Immunol"},{"key":"10.1006\/pupt.2002.0371_RF51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1165\/ajrcmb.20.1.3255","article-title":"B7 costimulation is required for IL-5 and IL-13 secretion by bronchial biopsy tissue of atopic asthmatic subjects in response to allergen stimulation","volume":"20","author":"Jaffar","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1006\/pupt.2002.0371_RF52","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1165\/ajrcmb.23.5.3954","article-title":"CD40L, but not CD40, is required for allergen-induced bronchial hyperresponsiveness in mice","volume":"23","author":"Mehlhop","year":"2000","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1006\/pupt.2002.0371_RF53","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1084\/jem.193.3.387","article-title":"Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40","volume":"193","author":"Jember","year":"2001","journal-title":"J Exp Med"},{"key":"10.1006\/pupt.2002.0371_RF54","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0006-2952(99)00378-0","article-title":"Advances in immunopharmacology of asthma","volume":"59","author":"Wong","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1006\/pupt.2002.0371_RF55","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1164\/ajrccm.160.6.9808146","article-title":"Interleukin-4 receptor in moderate atopic asthma. A phase I\/II randomized, placebo-controlled trial","volume":"160","author":"Borish","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF56","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1067\/mai.2001.115624","article-title":"Efficacy of soluble IL-4 receptor for the treatment of adults with asthma","volume":"107","author":"Borish","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1006\/pupt.2002.0371_RF57","first-page":"A505","article-title":"Results of a Phase I trial with SCH 55700, a humanized anti-IL-5 antibody, in severe persistent asthma","volume":"161","author":"Kips","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF58","first-page":"A 624","article-title":"SB 240563 a humanized anti-IL-5 monoclonal antibody initial single dose safety and activity in patients with asthma","volume":"159","author":"Leckie","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/rr42","article-title":"Th2 cytokines and asthma: Interleukin-9 as a therapeutic target for asthma","volume":"2","author":"Zhou","year":"2001","journal-title":"Respir Res"},{"key":"10.1006\/pupt.2002.0371_RF60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1067\/mai.2001.112265","article-title":"IL-12\/IL-13 axis in allergic asthma","volume":"107","author":"Wills-Karp","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1006\/pupt.2002.0371_RF61","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1126\/science.282.5397.2258","article-title":"Interleukin-13: central mediator of allergic asthma [see comments]","volume":"282","author":"Wills-Karp","year":"1998","journal-title":"Science"},{"key":"10.1006\/pupt.2002.0371_RF62","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1126\/science.282.5397.2261","article-title":"Requirement for IL-13 independently of IL-4 in experimental asthma [see comments]","volume":"282","author":"Grunig","year":"1998","journal-title":"Science"},{"key":"10.1006\/pupt.2002.0371_RF63","first-page":"A844","article-title":"Effect of anti-mIL-9 antibody on the development of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice [abstract]","volume":"161","author":"Kung","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF64","first-page":"A593","article-title":"Lung delivery of blocking IL9 antibody inhibits airway hyperresponsiveness, Bal eosinophilia, mucin production, serum IgE elevation to natural antigens in a murine model of asthma [abstract]","volume":"161","author":"Mclane","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1365-2222.2000.00091.x","article-title":"Reducing IgE levels as a strategy for the treatment of asthma","volume":"30","author":"Fahy","year":"2000","journal-title":"Clin Exp Allergy"},{"key":"10.1006\/pupt.2002.0371_RF66","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","article-title":"Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group","volume":"341","author":"Milgrom","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1006\/pupt.2002.0371_RF67","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1002\/(SICI)1521-4141(199909)29:09<2957::AID-IMMU2957>3.0.CO;2-4","article-title":"Critical role of CD23 in allergen-induced bronchoconstriction in a murine model of allergic asthma","volume":"29","author":"Dasic","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1006\/pupt.2002.0371_RF68","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1365-2222.2000.00812.x","article-title":"Inhibition of CD23 processing correlates with inhibition of IL-4-stimulated IgE production in human PBL and hu-PBL-reconstituted SCID mice","volume":"30","author":"Mayer","year":"2000","journal-title":"Clin Exp Allergy"},{"key":"10.1006\/pupt.2002.0371_RF69","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1164\/ajrccm.161.3.9905046","article-title":"CD23 exhibits negative regulatory effects on allergic sensitization and airway hyperresponsiveness","volume":"161","author":"Haczku","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1006\/pupt.2002.0371_RF70","first-page":"93","article-title":"New advances in the pathogenesis and therapy of bronchial asthma","volume":"13","author":"Ricci","year":"1998","journal-title":"Ann Ital Med Int"},{"key":"10.1006\/pupt.2002.0371_RF71","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1440-1711.2001.00980.x","article-title":"Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma","volume":"79","author":"Thomas","year":"2001","journal-title":"Immunol Cell Biol"},{"key":"10.1006\/pupt.2002.0371_RF72","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0014-2999(95)00463-U","article-title":"Induction of human airway hyperresponsiveness by tumour necrosis factor-alpha","volume":"284","author":"Anticevich","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1006\/pupt.2002.0371_RF73","first-page":"281","article-title":"SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence","volume":"293","author":"Underwood","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1006\/pupt.2002.0371_RF74","first-page":"67","article-title":"Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways","volume":"49","author":"Gater","year":"1998","journal-title":"Agents Actions Suppl"},{"key":"10.1006\/pupt.2002.0371_RF75","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0091-6749(98)70118-6","article-title":"Biologic activities of IL-1 and its role in human disease","volume":"102","author":"Rosenwasser","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1006\/pupt.2002.0371_RF76","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1165\/ajrcmb.11.4.7917315","article-title":"Interleukin-1 receptor antagonist protein inhibits the synthesis of IgE and proinflammatory cytokines by allergen-stimulated mononuclear cells","volume":"11","author":"Sim","year":"1994","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1006\/pupt.2002.0371_RF77","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0091-6749(95)70081-1","article-title":"Potential role of Interleukin-1 in allergen-induced late asthmatic reactions in guinea pigs: suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction","volume":"95","author":"Okada","year":"1995","journal-title":"J Allergy Clin Immunol"},{"key":"10.1006\/pupt.2002.0371_RF78","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1081-1206(10)62403-9","article-title":"Are chemokines essential or secondary participants in allergic responses?","volume":"84","author":"Gangur","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1006\/pupt.2002.0371_RF79","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.194.4.551","article-title":"Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation","volume":"194","author":"Lukacs","year":"2001","journal-title":"J Exp Med"},{"key":"10.1006\/pupt.2002.0371_RF80","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.165.4.2205","article-title":"Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells","volume":"165","author":"Sekiya","year":"2000","journal-title":"J Immunol"},{"key":"10.1006\/pupt.2002.0371_RF81","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1067\/mai.2000.107036","article-title":"Monocyte chemoattractant peptide-1 expression during cutaneous allergic reactions in mice is mast cell dependent and largely mediates the monocyte recruitment response","volume":"106","author":"Gordon","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1006\/pupt.2002.0371_RF82","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.4049\/jimmunol.158.10.4953","article-title":"Monocyte chemotactic protein-3 (MCP-3)\/fibroblast-induced cytokine (FIC) in eosinophilic inflammation of the airways and the inhibitory effects of an anti-MCP-3\/FIC antibody","volume":"158","author":"Stafford","year":"1997","journal-title":"J Immunol"},{"key":"10.1006\/pupt.2002.0371_RF83","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.4049\/jimmunol.166.3.2055","article-title":"Intervention of thymus- and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice","volume":"166","author":"Kawasaki","year":"2001","journal-title":"J Immunol"},{"key":"10.1006\/pupt.2002.0371_RF84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1067\/mai.2000.108112","article-title":"Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma","volume":"106","author":"Laberge","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1006\/pupt.2002.0371_RF85","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.4049\/jimmunol.160.6.2998","article-title":"Involvement of IL-16 in the induction of airway hyperresponsiveness and up-regulation of IgE in a murine model of allergic asthma","volume":"160","author":"Hessel","year":"1998","journal-title":"J Immunol"},{"key":"10.1006\/pupt.2002.0371_RF86","first-page":"15","article-title":"The role of adhesion molecules in allergic inflammation and their suitability as targets of antiallergic therapy","volume":"28","author":"Schleimer","year":"1998","journal-title":"Clin Exp Allergy"},{"key":"10.1006\/pupt.2002.0371_RF87","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1165\/ajrcmb.18.6.3056","article-title":"Reduction of antigen-induced airway hyperreactivity and eosinophilia in ICAM-1-deficient mice","volume":"18","author":"Wolyniec","year":"1998","journal-title":"Am J Respir Cell Mol Biol"}],"container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553902903718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553902903718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T15:51:21Z","timestamp":1704642681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553902903718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["S1094553902903718"],"URL":"https:\/\/doi.org\/10.1006\/pupt.2002.0371","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}